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Summary
Background—The calibrated automated thrombogram (CAT) assay measures thrombin generation
in plasma.
Objective—Use the CAT assay to detect endogenous tissue factor (TF) in recalcified platelet-rich
plasma (PRP) and platelet-free plasma (PFP).
Methods—Blood from healthy volunteers was collected into citrate and incubated at 37°C with or
without lipopolysaccharide (LPS) for 5 hours. PRP and PFP were prepared and clotting was initiated
by recalcification. Thrombin generation was measured using the CAT assay.
Results—The lag time (LT) was significantly shortened in PRP prepared from LPS-treated blood
compared with untreated blood (10 ± 3 min versus 20 ± 6 min), and this change was reversed by the
addition of inactivated human factor VIIa. LPS stimulation did not change the peak thrombin. Similar
results were observed in PFP (21 ± 4 min versus 35 ± 5 min). LPS stimulation also significantly
reduced the LT of PRP and PFP derived from blood containing citrate and a factor XIIa inhibitor.
Finally, a low concentration of exogenous TF shortened the LT of PFP prepared from unstimulated,
citrated blood without affecting the peak thrombin.
Conclusion—Changes in LT in the CAT assay can be used to monitor levels of endogenous TF in
citrated plasma.
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Tissue factor (TF) is a transmembrane glycoprotein that is essential for hemostasis (1-3).
Extravascular cells constitutively express TF to form a primary hemostatic barrier around blood
vessels (4). Following vessel injury TF activates the coagulation cascade leading to thrombin
generation, fibrin deposition and platelet activation. In pathological conditions, such as
endotoxemia and sepsis, TF is expressed by circulating monocytes (5-8). Indeed, several
studies have shown that bacterial lipopolysaccharide (LPS) induces TF expression in
monocytes and monocytic cells (4) (9-12). TF is also found in plasma in the form of
microparticles (MPs), which are small (< 1 μM) membrane vesicles generated by activated or
apoptotic cells (13). TF-positive MPs may contribute to thrombosis in patients with a variety
of diseases, including cardiovascular disease, sickle cell disease, endotoxemia and cancer
(14-23).
The level of TF in plasma can be measured using various methods. Enzyme-linked
immunosorbant assays and flow cytometry measure TF antigen (18) (24-27); however, because
antibodies may recognize “encrypted” TF or degraded forms of TF that are not active, levels
of TF antigen may not correlate with procoagulant activity. Recently, two groups have
described assays that measure MP TF activity (16) (19). One study captured the TF-positive
MPs with an antibody and showed that infusion of LPS into volunteers increased MP TF
activity (16). Another study isolated MPs by centrifugation and showed that patients with
advanced cancer had elevated levels of MP TF activity (19). We recently developed a similar
MP TF activity assay (28). It is worth noting, however, that these activity assays require
multiple steps and are time-consuming.
Hemker and colleagues developed the Calibrated Automated Thrombogram (CAT) assay to
measure thrombin generation in plasma (29). In this assay, thrombin generation is triggered
by the addition of low levels of recombinant, relipidated tissue factor or endogenous
procoagulant MPs (30-32). Thrombin generation is monitored via cleavage of a fluorogenic
substrate that allows the measurement of thrombin in the presence of fibrinogen and platelets
(33). Test samples are normalized for plasma color, inner filter effect and substrate depletion
to produce a thrombogram. Lag time (LT) and peak of thrombin generation can be derived
from the thrombogram. The CAT assay has been used for a variety of purposes, including
detection of clotting factor deficiencies, monitoring of warfarin therapy, and the efficiency of
replacement factor therapy in hemophiliacs (30) (34-36). Notably, it has also been used to
detect hypercoagulable states, including congenital heart disease, severe sepsis syndrome,
acute deep-vein thrombosis and patients at risk of recurrent venous thromboembolism
(37-40).
In this study, we examined if the CAT assay could be used to detect changes in endogenous
TF levels in platelet-rich plasma (PRP) and platelet-free plasma (PFP). We used a model system
of LPS-treated whole blood to generate TF. We found that the presence of endogenous TF in
PRP and PFP reduced the LT but did not affect the peak thrombin. These results indicate that
the LT in the CAT assay can be used to monitor levels of endogenous TF in plasma.
Materials and methods
Materials
LPS (Escherichia coli serotype O111:B4) was obtained from Sigma-Aldrich, St Louis, MO.
MP reagent (Diagnostica Stago, Asnières, France) was used as a source of phospholipids and
contains phosphatidylserine, phosphatidylcholine and phosphatidylethanolamine at a ratio of
20:60:20. The PRP reagent (Diagnostica Stago) was used as a source of recombinant TF. Corn
trypsin inhibitor (CTI) and factor XI were purchased from Haematologic Technologies, Inc
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(Essex Junction, VT). Factor XI-deficient plasma was purchased from HRF, Inc (Raleigh, NC).
Human factor VIIa and factor X were purchased from Enzyme Research Laboratories (South
Bend, IN). Factor VIIai was obtained from American Diagnostica (Stamford, CT).
Whole blood collection, LPS stimulation and preparation of PRP and PFP
Venous blood was obtained from healthy consenting volunteers not currently taking any
medication. Blood was collected via atraumatic antecubital venipuncture into siliconized
Vacutainer™ tubes (Becton Dickinson, Meyton, France) containing buffered sodium citrate
(0.129 M, nine parts blood to one part sodium citrate solution). The first tube of blood was
discarded. In some experiments CTI (18.3 μg/ml final concentration) was added to the
Vacutainer™ tubes prior to blood draw (41). Whole blood was incubated at 37°C with or
without LPS for 5 hours. After incubation, whole blood was centrifuged at 200g for 15 min at
room temperature to prepare PRP. Platelet counts in PRP were adjusted to150,000 platelets/
μl (final) by dilution with autologous PFP. PFP was prepared by centrifuging PRP at 2000g
for 15 min followed by a 13,000g spin for 2 min to remove any remaining platelets. MP-
depleted plasma was prepared by centrifuging PFP at 20,000g for 15 min. Thrombin generation
was measured in freshly prepared PRP and PFP.
Thrombin generation
Thrombin generation was measured using a Thrombinoscope (Thrombinoscope BV,
Maastricht, Netherlands). Briefly, 80 μl of each sample was mixed with 20 μl of HEPES
buffered-saline (pH 7.35, 20 mM HEPES, 140 mM NaCl, 5 mg/ml bovine serum albumin).
Samples spiked with 20 μl thrombin calibrator (Diagnostica Stago, Asniéres, France) were run
in parallel with each cycle of test sample. Thrombin generation was triggered by addition of
CaCl2 (16.7 nM final concentration) and fluorogenic substrate Z-Gly-Gly-Arg-AMC (417
μM final concentration, pH 7.5, 20 mM HEPES, 60 g/l bovine serum albumin). The
Thrombinoscope software measures several parameters including LT, peak of thrombin
generation and endogenous thrombin potential (ETP), which correlates to the area under the
thrombogram curve. The contribution of TF to thrombin generation was assessed by
preincubating samples at room temperature for 10 min with inactivated factor VIIa (FVIIai)
(100 nM).
MP TF Activity Assay
We have recently described a MP TF activity assay (28). Briefly, MPs were isolated from PFP
by centrifugation at 20,000g for 15 min at 4 °C, washed twice and resuspended in buffer.
Samples were incubated with either an inhibitory anti-human TF monoclonal antibody (HTF1)
(42) or a control mouse IgG for 15 min at room temperature before performing a two-stage
chromogenic assay with human factor VIIa and human factor X. TF-dependent factor Xa
generation (pg/ml) was determined by subtracting the amount of factor Xa generated in the
presence of HTF1 from the amount of factor Xa generated in the presence of the control
antibody.
Statistical analysis
Data are expressed as mean ± standard deviation (SD). Differences between experimental
conditions were analyzed using a one-tailed Student’s t-test. A probability value p < 0.05 was
considered statistically significant.
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Thrombin generation in PRP and PFP prepared from citrated blood with or without LPS
stimulation
The LT of PRP isolated from LPS-treated blood was significantly shorter than the LT of PRP
isolated from blood without LPS stimulation (10 ± 3 min versus 20 ± 6 min) (Fig. 1A). Addition
of FVIIai reversed the LPS-dependent shift in LT indicating that the change was due to the
expression of TF. Similar results were observed using an inhibiting anti-human TF antibody
called HTF1 (10 μg/ml) (data not shown). LPS stimulation did not change the peak of thrombin
generation or the ETP in PRP (Fig. 1B and data not shown). LPS treatment also shortened the
LT in PFP (21 ± 4 min versus 35 ± 5 min), which was reversed by factor VIIai (Fig. 2A). The
peak of thrombin generation was not significantly affected by LPS treatment (Fig. 2B). Of
note, levels of thrombin were higher in PRP compared with PFP.
LPS dose response
Our initial studies used a high dose of LPS to potently stimulate the blood. We next determined
if LPS produced a dose-dependent change in the LT. We found that LPS induced a dose-
dependent shortening of the LT in both PRP and PFP (Fig. 3A and 3B). Consistent with our
earlier findings, the peak for both PRP and PFP was not significantly affected by addition of
different doses of LPS (data not shown). A significant difference in LT was observed in PRP
with lower doses of LPS compared with PFP, which is most likely due to the larger amounts
of thrombin generated in PRP.
Role of factor XIIa in thrombin generation in PRP and PFP from untreated and LPS-treated
blood
To discern TF triggered thrombin generation from contact activation we compared results from
blood collected into tubes containing citrate alone with those using blood collected into tubes
containing citrate and CTI, a factor XIIa inhibitor. We found that CTI prolonged the LT in PRP
and PFP from unstimulated blood, but did not significantly change the LT in PRP and PFP
from LPS-stimulated blood (Fig. 4A and C). Importantly, LPS treatment significantly
shortened the LT of PRP and PFP derived from blood containing citrate and CTI (Fig. 4A and
C). CTI decreased the peak of thrombin generation in both PRP and PFP from unstimulated
and LPS-stimulated blood (Fig. 4B and D). Importantly, LPS treatment significantly shortened
the LT of PRP and PFP derived from blood containing citrate and CTI.
Effect of exogenous phospholipids on thrombin generation
We hypothesized that PFP had a prolonged LT compared with PRP because PFP had a limited
amount of phospholipid surface for assembly of the coagulation protein complexes. Therefore,
we examined the effect of adding exogenous phospholipids on thrombin generation. Addition
of exogenous phospholipids to the PFP caused a dose-dependent reduction of the LT and an
increase in the peak of thrombin in both untreated and LPS-treated blood (Fig. 5A and B).
MPs are the primary source of TF in PFP from LPS-treated blood
To investigate the contribution of MPs to thrombin generation in our in vitro model, we
analyzed the effect of depleting MPs by centrifugation at 20,000g for 15 min. This procedure
was designed to remove large MPs but not small MPs. We found that the LT of PFP from both
untreated and LPS-treated blood was prolonged in plasma depleted of MPs (Fig. 6A). The
shorter LT observed in MP-depleted PFP derived from LPS-treated blood compared with MP-
depleted PFP derived from untreated blood is likely due to the presence of residual, small TF-
positive MPs in the plasma from LPS-treated blood. Next, we directly measured the TF activity
of MPs isolated from untreated and LPS-treated whole blood. LPS stimulation dramatically
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increased the level of TF activity in isolated MPs (Fig. 6B). These results suggest that MP TF
activity is the major source of TF in PFP isolated from LPS stimulated blood.
Interestingly, direct stimulation of PRP with LPS for 5 hours did not change the LT or peak,
suggesting that TF expression was not inducible in platelets (data not shown). In addition, we
found that stimulation of PRP with a PAR-1 agonist peptide (50 μM) shortened the LT (7 min
versus 10 min) and increased the peak (427 nm versus 137 nm). The shortening of the LT by
the PAR-1 agonist peptide was not affected by FVIIai (data not shown).
Exogenous TF dose response in PFP
We analyzed the effect of exogenous TF on thrombin generation in PFP generated from blood
collected into citrate alone or citrate and CTI. Although the effect of TF on thrombin generation
has previously been characterized, no studies have examined the effect of 0-1 pM TF
concentrations on thrombin production. To produce a shift in LT that was similar to that
observed in PFP prepared from LPS-treated blood we used low concentrations of exogenous
TF. Phospholipids (4μM) were added to all the samples. Exogenous TF induced a dose-
dependent shortening of the LT with no change in peak thrombin in PFP from citrated blood
(Fig. 7A and B). However, at high concentrations of recombinant TF (> 1 pM) an increase in
peak was observed (data not shown). In blood anticoagulated with citrate and CTI exogenous
TF changed both the LT and the peak thrombin (Fig. 7C and D). We also found that exogenous
TF changed the LT and peak in factor XI-deficient plasma and that the effect on peak was lost
upon addition of factor XI (final concentration 4μg/mL) to the factor XI-deficient plasma
(Table). These results indicate that TF can affect the peak of thrombin generation when the
intrinsic pathway is inhibited or deficient.
Discussion
The goal of this study was to determine if the CAT assay could be used to detect endogenous
TF activity in plasma. Normally, the CAT assay uses recombinant TF to initiate coagulation
and has been used extensively to measure thrombin generation in a variety of clinical samples.
We found that the CAT assay could be used to measure increased levels of endogenous TF in
both PRP and PFP prepared from citrated blood stimulated with LPS. The presence of TF
shortened the LT but did not affect the peak of thrombin generation. Similar results were
observed when low levels of recombinant TF were added to PFP prepared from unstimulated
blood. Based on our studies with exogenous TF we estimate that PFP from LPS-treated blood
contains <0.2 pM of TF. These results indicate that low levels of endogenous TF contribute to
the initiation of clotting without significantly affecting the amount of thrombin generated in
citrated plasma.
We used LPS-treated whole blood as a model system to generate endogenous TF. LPS is a
potent inducer of TF expression in monocytes (4) (9-10). We found that LPS induced a dose-
dependent shortening of the LT in both PRP and PFP. Depletion of the MPs by centrifugation
significantly prolonged the LT in PFP prepared from LPS-treated blood. In addition, isolated
MPs from LPS-treated blood contained TF activity. These results suggest that MPs are a major
source of TF in LPS-treated blood. A recent study used the CAT assay to measure the
procoagulant activity of MPs derived from patients with recurrent thrombosis (31).
Interestingly, the LT in PFP from blood incubated without LPS for 5 hours was also prolonged
by depletion of the MPs, suggesting that small amounts of MPs generated under these
conditions initiate the clotting reaction. LPS induces the release of TF-positive MPs from
monocytes and these MPs can bind to activated platelets (43). Platelets have also been reported
to express TF, although this is controversial (44-47). Therefore, TF-positive MPs observed in
our study could be derived from monocytes and/or platelets. We found that direct stimulation
of PRP did not shorten the LT, suggesting that either direct stimulation of platelets with LPS
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does not induce TF expression or that the levels of TF generated from platelets are below the
detectable threshold of the CAT assay. Although we cannot exclude the possibility that other
factors in LPS-treated whole blood induce TF expression in platelets, our results suggest that
LPS stimulation of whole blood induces TF expression in monocytes and that these cells release
TF-positive MPs that are present in both PRP and PFP.
We found that the LT observed in PRP was shorter than the LT of PFP prepared from LPS-
treated blood. In addition, the peak of thrombin generation was much higher in PRP compared
with PFP. We suspected that this was due, in part, to a limited amount of phospholipid surface
in the PFP. Indeed, consistent with other studies, addition of exogenous phospholipids
shortened the LT and increased the peak of thrombin generation (36) (48). A MP reagent
containing phospholipids has been developed to measure the procoagulant activity of MPs in
plasma. However, we found that the addition of exogenous phospholipids dramatically reduced
the difference in LT between PFP prepared from untreated versus LPS-treated blood,
suggesting that this reagent may reduce the TF-dependence of the assay.
The intrinsic coagulation pathway is involved in the amplification of thrombin generation
during blood coagulation. Collecting blood into tubes containing citrate alone is associated
with activation of factor XII (41). We investigated the role of factor XIIa in thrombin generation
by comparing results using PRP and PFP prepared from blood collected into citrate alone or
citrate plus CTI. We found that inhibition of factor XIIa significantly prolonged the LT and
decreased the peak in PRP and PFP prepared from untreated blood. CTI also decreased the
peak thrombin but did not significantly prolong the LT in PRP and PFP from LPS-treated
blood. Similarly, CTI prolonged the LT at low doses of exogenous TF (0.025-0.1 pM) but not
at a high dose of TF (0.2 pM). Consistent with our results, several studies showed that factor
XI contributes to thrombin generation when low concentrations of recombinant TF are used
in the CAT assay (41) (49) (50). These results indicate that factor XIIa plays a major role
initiating and amplifying the coagulation cascade in untreated blood that contains very low
levels of TF but contributes less to the initiation phase of clotting in the presence of high levels
of TF. Interestingly, low levels of exogenous TF affected the LT but not the peak in citrated
plasma but affected the LT and the peak in citrated plasma with CTI. Similarly, low levels of
exogenous TF shortened the LT and increased the peak in factor XI-deficient plasma but not
in factor XI-deficient plasma with factor XIa. These results support the notion that the major
role of TF in blood coagulation is to initiate the cascade and that it has a minimal role in
amplification of thrombin generation when the intrinsic pathway is not inhibited. Nevertheless,
there are several disadvantages to using CTI: it is expensive; it requires special collection of
the blood; and it dramatically reduces the amounts of thrombin generated in the CAT assay.
The strength of the CAT assay is the measurement of thrombin generation in native plasma.
One limitation of the CAT assay is that it is affected by changes in the levels of clotting factors.
For instance, levels of clotting factors decrease in patients with a consumptive coagulopathy
and this could lead to a decrease in thrombin generation even in the presence of increased TF
levels. One study showed that sepsis patients had prolonged LT and decreased peak thrombin
compared with controls due to decreased levels of clotting factors (51). Our studies indicate
that the CAT assay can detect levels of endogenous TF in plasma. However, there are several
factors to consider when using the CAT assay. Inhibition of FXIIa with CTI prolongs the LT
and makes thrombin generation more dependent on the presence of TF. Addition of exogenous
phospholipids increases thrombin generation by providing a thrombogenic surface but may
decrease the TF-dependence of the reaction. Factors other than TF can affect thrombin
generation and therefore CAT assays should be performed in the presence and absence of an
inhibitor of TF to determine the contribution of TF to thrombin generation. Despite the positive
results from this LPS whole blood model, further studies are required to determine if the CAT
assay can be used to detect elevated levels of MP TF activity in clinical samples.
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Figure 1. Thrombin generation in LPS-treated PRP
PRP was prepared from citrated human whole blood that was treated with either PBS control
(white bars) or LPS (10 μg/mL) (black bars) for 5 h at 37°C. PRP was recalcified and thrombin
generation measured using the CAT assay. PRP from LPS stimulated blood was also
preincubated with factor VIIai (100 nM) (hatched bars) for 10 min at room temperature prior
to measuring thrombin generation. Two parameters of thrombin generation are shown (mean
± SD, n = 15): LT (Panel A), peak (Panel B). The asterisk indicates a statistically significant
difference from the control p < 0.05.
Ollivier et al. Page 10













Figure 2. Thrombin generation in LPS-treated PFP
PFP was isolated from citrated human whole blood that was treated with either PBS control
(white bars) or LPS (10 μg/mL) (black bars) for 5 h at 37°C. PFP was recalcified and thrombin
generation measured using the CAT assay. PFP from LPS stimulated blood was also
preincubated with factor VIIai (100 nM) (hatched bars) for 10 min at room temperature prior
to measuring thrombin generation. Two parameters of thrombin generation are shown (mean
± SD, n = 6): LT (Panel A) and peak (Panel B). The asterisk indicates a statistically significant
difference from the control p < 0.05.
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Figure 3. LPS dose response
Citrated whole blood was treated with PBS control or LPS (0.1, 1 and 10 μg/mL) for 5 h
followed by preparation of PRP and PFP. Thrombin generation in PRP (Panel A) and PFP
(Panel B) was measured using the CAT assay. The LT of thrombin generation is shown (mean
± SD, n = 5). Asterisks indicate a statistically significant difference from the control p < 0.05.
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Figure 4. Role of factor XIIa in thrombin generation in PRP and PFP
Whole blood was anticoagulated with either sodium citrate alone (white Bars) or sodium citrate
and CTI (18.3 μg/mL) (black bars) and incubated at 37°C for 5 h with or without LPS (10 μg/
ml. Thrombin generation in recalcified PRP (Panels A and B, n=4 ) and PFP (Panels C and D,
n=4 ) was measured using the CAT assay. Data are shown as mean ± SD. Asterisks indicate a
statistically significant difference from the control p < 0.05.
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Figure 5. Effect of exogenous phospholipids on thrombin generation in PFP
PFP was prepared from whole blood with or without LPS stimulation. Phospholipids (0, 0.5,
1 and 4 μM) were added to PFP before measuring thrombin generation. Results (mean ± SD,
n=4) from PFP prepared from untreated (white bars) and LPS-treated (black bars) are shown.
Asterisks indicate a statistically significant difference from the control p < 0.05.
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Figure 6. Role of MPs in thrombin generation in PFP from untreated and LPS-treated blood
A/ Thrombin generation was measured in PFP (white bars) or PFP depleted of MPs (black
bars). MPs in PFP were depleted by centrifugation at 20,000g for 20 min. Results from PFP
prepared from untreated and LPS (10 μg/ml)-treated blood are shown as mean ± SD, n= 5
(Panel A). B/ MPs were prepared from PFP that was prepared from untreated (white bar) or
LPS-treated (black bars) blood (n=3). MP TF activity was measured in a two-stage
chromogenic assay. Asterisks indicate a statistically significant difference from the control p
< 0.05.
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Figure 7. Effect of exogenous TF on thrombin generation in PFP with of without inhibition of FXIIa
Whole blood was collected into either sodium citrate or sodium citrate and CTI and used to
prepare PFP. Exogenous TF (0.025-1.0 pM) and phospholipid (4 μM) were added to PFP from
citrated blood (Panels A and B) or PFP from blood anticoagulated with citrate and CTI (Panels
C and D) and the LT and peak of thrombin generation measured. Data are shown as mean ±
SD (n=3). Asterisks indicate a statistically significant difference from the control p < 0.05.
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Table
Effect of exogenous TF on thrombin generation in factor XI-deficient plasma with or without factor XI.
TF (pM)
FXI-deficient plasma FXI-deficient plasma + FXI
LT (min) Peak (nM) LT (min) Peak (nM)
0 ND 0 16.7 147.5
0.025 ND 0 10.5 129.5
0.05 ND 0 9.8 132.0
0.1 24.5 2.4 9.3 123.0
0.2 12.5 5.8 8.2 145.5
1.0 5.7 28.9 5.2 125.0
ND — Not Detectable. MP reagent (4 μM) was added to each reaction. Data is shown as mean of two independent experiments.
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